BIOPHYTIS (EPA:ALBPS) - Biophytis to participate in upcoming sectorial events over the first half of 2018

Transparency directive : regulatory news

02/02/2018 18:00

Press Release

Biophytis to participate in upcoming sectorial events over the first half of
2018

Paris (France), February 2nd, 2018, 6 pm - BIOPHYTIS (Euronext Growth Paris:
ALBPS), a biotechnology company specializing in the development of drug
candidates to treat age-related diseases, will participate in the upcoming to
key scientific, investors and partnering events in France, Europe and America
during the first half of 2018.

Investors' events

* CF&B European Midcap Event Frankfurt - February 6th, 2018 (Frankfurt,
Germany)
* HC Wainwright & Co Life Sciences Conference - April 8th - 10th, 2018 (Monaco)
* CF&B Small Cap event - April 16th - 17th, 2018 (Paris, France)

Scientific events

* ICFSR 2018 - March 1st- 3rd 2018 (Miami Beach, United-States)
* ARVO - April 29th - 3rd May 2018 (Honolulu, United-States)

Partnering conferences

* BIO-Europe - 5th- 7th November 2018 (Copenhagen, Denmark)
* BIO 2018 - 4th - 7th June 2018 (Boston, United-States)

About BIOPHYTIS:

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates
targeting diseases of aging. Using its technology and know-how, Biophytis has
begun clinical development of innovative therapeutics to restore the muscular
and visual functions in diseases with significant unmet medical needs.
Specifically, the company is advancing two lead products into mid-stage
clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and
Macuneos (BIO201) to treat dry age-related macular degeneration (AMD).

The business model of BIOPHYTIS is to ensure the conduct of the project until
clinical activity in the patient is proven, then to license the technologies in
order to continue the development in partnership with a pharmaceutical
laboratory.
The company was founded in partnership with researchers at the UPMC (Pierre and
Marie Curie University) and also collaborates with scientists at the Institute
of Myology, and the Vision Institute.

BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS;
ISIN: FR0012816825).

For more information: http://www.biophytis.com

Follow us on Twitter @biophytis

BIOPHYTIS is eligible for the SMEs scheme

Disclaimer
This press release contains certain forward-looking statements. Although the
Company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the Company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Listing Prospectus upon the
admission of Company's shares for trading on the regulated market Euronext
Growth of Euronext Paris filed with the AMF, which is available on the AMF
website (www.amf- france.org) or on BIOPHYTIS' website (www.biophytis.com).

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
BIOPHYTIS in any country. Items in this press release may contain
forward-looking statements involving risks and uncertainties. The Company's
actual results could differ substantially from those anticipated in these
statements owing to various risk factors which are described in the Company's
prospectus. This press release has been prepared in both French and English. In
the event of any differences between the two texts, the French language version
shall prevail.

BIOPHYTIS
Stanislas VEILLET CEO
contact@biophytis.com
Tel: +33 (0) 1 44 27 23 00

Citigate Dewe Rogerson
Presse internationale & Investisseurs
Laurence BAULT/Antoine DENRY
Laurence.bault@citigatedewerogerson.com
antoine.denry@citigatedewerogerson.com
Tel: +33 (0)1 53 32 84 78
Mob: +33(0)6 64 12 53 61

LifeSci Advisors
Chris MAGGOS
Managing Director, Europe
chris@lifesciadvisors.com
Tel: +41 79 367 6254

BIOPHYTIS's latest news

19/04/2024 07:00

BIOPHYTIS (EPA:ALBPS) - Biophytis to participate in upcoming sectorial events over the first half of 2018

Transparency directive : regulatory news

BIOPHYTIS's latest news

Other stories